Skip to main content
. Author manuscript; available in PMC: 2008 Jan 14.
Published in final edited form as: Semin Oncol. 2007 Dec;34(6):524–531. doi: 10.1053/j.seminoncol.2007.09.002

Table 2.

Clinical Responses to treatment

Patient1 Sites of Treated Disease Response Duration (months)2
1 Axillary, Mesenteric, and Pelvic Lymph Nodes PR 29
2 Subcutaneous and Skin PR 8
4 Iliac and Inguinal Lymph Nodes, Skin PR 2
6 Intraperitoneal Lymph Nodes, Lungs, Subcutaneous PR 23
9 Subcutaneous and Skin PR 11
10 Inguinal Lymph Nodes, Subcutaneous and Skin PR 14
16 Subcutaneous CR 58+
17 Bone, Liver, Lung, Subcutaneous CR 57+
19 Intramuscular PR 13
21 Lung, Subcutaneous CR 51+
25 Lung, Subcutaneous PR 2
26 Inguinal Lymph Nodes, Liver, Subcutaneous PR 8
28 Axillary Lymph Nodes, Brain PR 4
30 Axillary and Inguinal Lymph Nodes, Intramuscular, Subcutaneous PR 7
31 Liver, Lung CR 41+
32 Skin CR 40+
33 Lung, Subcutaneous PR 2
34 Intramuscular, Pelvis PR 3
1

Patients 2, 6, and 17 had minor (Patient 6) or mixed (Patient 2 and Patient 17) responses after a first course of treatment, and were treated with a second course of treatment consisting of ablation, cell transfer and high dose IL-2 therapy prior to achieving an objective clinic response.

2

Measured from treatment date to time of first recurrence. Patients 16, 17, 21, 31 and 32 had ongoing responses as of May, 2007.

3

Adapted from Dudley et al., 2005 (Reference 23).